Irinotecan Aurobindo (Irinotecan Hydrochloride Trihydrate)

Irinotecan is a prodrug that is converted in the body to the active metabolite SN‑38. SN‑38 inhibits DNA topoisomerase I, preventing the re‑ligation of single‑strand DNA breaks, which leads to DNA damage and ultimately stops tumor cell replication.

The dosing of Irinotecan is individualized by the prescribing oncologist. Factors such as the patient’s body surface area, disease stage, prior therapies, and organ function determine the exact amount and schedule, and these details are not publicly standardized.

Safety of Irinotecan during pregnancy and lactation has not been established. Because of potential fetal toxicity and excretion in breast milk, it is generally avoided unless the therapeutic benefit clearly outweighs the potential risk to the fetus or infant.

To order, submit an enquiry on the Irinotecan Aurobindo product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any required import documentation.

Compared with other topoisomerase I inhibitors such as topotecan, Irinotecan has a distinct metabolic activation to SN‑38 and is commonly used in fluorouracil‑based regimens for colorectal cancer. Its efficacy and toxicity profile differ, with Irinotecan often causing more pronounced diarrhea and neutropenia, while topotecan may have a different dosing schedule and side‑effect spectrum.

Irinotecan Aurobindo must be stored at 2‑8 °C, protected from light, and kept in its original packaging. It should not be frozen or shaken. Once reconstituted, the solution should be used promptly according to the manufacturer’s instructions and any remaining product discarded if not used within the recommended time.

The medication is supplied as a sterile powder for intravenous infusion. After reconstitution with the appropriate diluent, it is filtered if required and administered by a qualified healthcare professional over a prescribed infusion period, typically under clinical monitoring for adverse reactions.

The most serious adverse events include severe neutropenia, febrile neutropenia, grade 3‑4 diarrhea that can lead to dehydration, intestinal perforation, and rare life‑threatening allergic reactions. Patients should be closely monitored for signs of infection, persistent diarrhea, abdominal pain, or any hypersensitivity symptoms.

Irinotecan should be avoided in patients with known hypersensitivity to the drug or its excipients, those with uncontrolled infections, significant bone‑marrow suppression, severe hepatic impairment, or pregnant women unless the potential benefit justifies the risk. Clinical judgment is essential to determine suitability.